HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: An IgA gene and functional analysis

Mucosal Immunology

Volumn 2, Issue 5, 2009, Pages 412-426

  Tudor, D ^a,b   Derrien, M ^a,b   Diomede, L ^c   Drillet, A S ^a,b   Houimel, M ^a,b   Moog, C ^d   Reynes, J M ^e   Lopalco, L ^c   Bomsel, M ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e Institut Pasteur du Cambodge   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2F5 ANTIBODY; IMMUNOGLOBULIN G4E10 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SERODIAGNOSIS; SOMATIC MUTATION; TRANSCYTOSIS; UTERINE CERVIX; VAGINA SECRETION; VIRUS NEUTRALIZATION;

EID: 69249086612     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2009.89     Document Type: Article

References (75)

1. Mazzoli, S. et al. HIV-specific mucosal and cellular immunity in HIVseronegative partners of HIV-seropositive individuals. Nat. Med. 3, 1250-1257 (1997).
2. Piacentini, L., Fenizia, C., Naddeo, V. & Clerici, M. Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine 26, 3002-3007 (2008).
3. Hirbod, T. & Broliden, K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J. Intern. Med. 262, 44-58 (2007).
4. Miyazawa, M., et al. & group f. t. E. s. The "immunologic advantage" of HIV-exposed seronegative individuals. AIDS 23 161-175 (2009).
5. Biasin, M. et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: A possible role in the resistance to HIV of HIVexposed seronegative individuals. J. Infect. Dis. 195, 960-964 (2007).
6. Nguyen, M. et al. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J. Acquir. Immune. Defic. Syndr. 42, 412-419 (2006).
7. Ghys, P.D. et al. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Cote d' Ivoire. AIDS 14, 2603-2608 (2000).
8. Lopalco, L. et al. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J. Gen. Virol. 86, 339-348 (2005).
9. Devito, C. et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165, 5170-5176 (2000).
10. Devito, C. et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J. Acquir. Immune. Defic. Syndr. 30, 413-420 (2002).
11. Alfsen, A., Iniguez, P., Bouguyon, E. & Bomsel, M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166, 6257-6265 (2001).
12. Belec, L. et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis. 184, 1412-1422 (2001).
13. Clerici, M. et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 16, 1731-1741 (2002).
14. Horton, R.E. et al. Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res. Hum. Retroviruses 25, 83-92 (2009).
15. Kaul, R., Plummer, F., Clerici, M., Bomsel, M., Lopalco, L. & Broliden, K. Mucosal IgA in exposed, uninfected subjects: Evidence for a role in protection against HIV infection. AIDS 15, 431-432 (2001).
16. Ofek, G. et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737 (2004).
17. Ferrantelli, F. & Ruprecht, R.M. Neutralizing antibodies against HIV - back in the major leagues? Curr. Opin. Immunol. 14, 495-502 (2002).
18. Hocini, H. et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: Contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res. Hum. Retroviruses 13, 1179-1185 (1997).
19. Bomsel, M. et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9, 277-287 (1998).
20. Huang, Y.T., Wright, A., Gao, X., Kulick, L., Yan, H. & Lamm, M.E. Intraepithelial cell neutralization of HIV-1 replication by IgA. J. Immunol. 174, 4828-4835 (2005).
21. Alfsen, A. & Bomsel, M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 277, 25649-25659 (2002).
22. Salzwedel, K., West, J.T. & Hunter, E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73, 2469-2480 (1999).
23. Fantini, J., Cook, D.G., Nathanson, N., Spitalnik, S.L. & Gonzalez-Scarano, F. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl Acad. Sci. USA 90, 2700-2704 (1993).
24. Magerus-Chatinet, A., Yu, H., Garcia, S., Ducloux, E., Terris, B. & Bomsel, M. Galactosyl ceramide expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to autologous T cells. Virology 362, 67-74 (2007).
25. Coutant, J. et al. Both lipid environment and pH are critical for determining physiologic solution structure of 3D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J. 22, 4338-4351 (2008).
26. Matoba, N. et al. Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. Curr. HIV Res. 6, 218-229 (2008).
27. Matoba, N. et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc. Natl Acad. Sci. USA 101, 13584-13589 (2004).
28. Zhang, M.Y. et al. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J. Virol. 82, 6869-6879 (2008).
29. Alsmadi, O. & Tilley, S.A. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities. J. Virol. 72, 286-293 (1998).
30. Sblattero, D. & Bradbury, A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology 3, 271-278 (1998).
31. Barbas, C.F. III, Burton, D.R., Scott, J.K. & Silverman, G.J. Phage Display: A Laboratory Manual (Cold Spring Harbor Laboratory Press, New York) (2001).
32. Delcroix-Genete, D., Quan, P.L., Roger, M.G., Hazan, U., Nisole, S. & Rousseau, C. Antiviral properties of two trimeric recombinant gp41 proteins. Retrovirology 3, 16 (2006).
33. Skerra, A. A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments. Gene 141, 79-84 (1994).
34. Nakowitsch, S., Quendler, H., Fekete, H., Kunert, R., Katinger, H. & Stiegler, G. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 19, 1957-1966 (2005).
35. Haynes, B.F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005).
36. Scherer, E.M., Zwick, M.B., Teyton, L. & Burton, D.R. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21, 2131-2139 (2007).
37. Vcelar, B. et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 21, 2161-2170 (2007).
38. Polonis, V.R. et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375, 315-320 (2008).
39. Brandtzaeg, P. et al. Regional specialisation in the mucosal immune system: What happens in the microcompartments? Immnunol. Today 20, 141-151 (1999).
40. Pandey, J. Genetics of immunoglobulins. Immunol. Ser. 58, 103-116 (1993).
41. Zouali, M. Unravelling antibody genes. Nat. Genet. 7, 118-120 (1994).
42. Viau, M. & Zouali, M. Molecular determinants of the human antibody response to HIV-1: Implications for disease control. J. Clin. Immunol. 21, 410-419 (2001).
43. Azzazy, H.M. & Highsmith, W.E. Jr. Phage display technology: Clinical applications and recent innovations. Clin. Biochem. 35, 425-445 (2002).
44. Saphire, E.O. et al. Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science 293, 1155-1159 (2001).
45. Zwick, M.B. et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing antihuman immunodeficiency virus type 1 antibody 2F5. J. Virol. 78, 3155-3161 (2004).
46. Barbas, C.F. III. et al. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230, 812-823 (1993).
47. de Wildt, R.M., Hoet, R.M., van Venrooij, W.J., Tomlinson, I.M. & Winter, G. Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J. Mol. Biol. 285, 895-901 (1999).
48. Hirbod, T. et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22, 727-735 (2008).
49. Alexander, R. & Mestecky, J. Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr. HIV Res. 5, 588-593 (2007).
50. Alfsen, A. & Bomsel, M. Entry of viruses through the epithelial barrier: pathogenic trickery. Nat. Rev. Mol. Cell Biol. 4, 57-68 (2003).
51. Apodaca, G., Bomsel, M., Arden, J., Breitfeld, P.P., Tang, K. & Mostov, K.E. The polymeric immunoglobulin receptor. A model protein to study transcytosis. J. Clin. Invest. 87, 1877-1882 (1991).
52. Mantis, N.J., Kozlowski, P.A., Mielcarz, D.W., Weissenhorn, W. & Neutra, M.R. Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 19, 3990-4001 (2001).
53. Hovanessian, A.G. et al. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity 21, 617-627 (2004).
54. Mantis, N.J. et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12V region. J. Immunol. 179, 3144-3152 (2007).
55. Wolbank, S., Kunert, R., Stiegler, G. & Katinger, H. Characterization of human class-switched polymeric (Immunoglobulin M [IgM] and IgA) antihuman immunodeficiency virus type 1 antibodies 2F5 and 2G12. J. Virol. 77, 4095-4103 (2003).
56. Bryson, S., Julien, J.P., Isenman, D.E., Kunert, R., Katinger, H. & Pai, E.F. Crystal structure of the complex between the F(ab)′ fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6. J. Mol. Biol. 382, 910-919 (2008).
57. Tonegawa, S. Somatic generation of antibody diversity. Nature 302, 575-581 (1983).
58. Xu, J.L. & Davis, M.M. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13, 37-45 (2000).
59. Morea, V., Tramontano, A., Rustici, M., Chothia, C. & Lesk, A. M. Conformations of the third hypervariable region in the VH domain of immunoglobulins. J. Mol. Biol. 275, 269-294 (1998).
60. Alam, S.M. et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178, 4424-4435 (2007).
61. Veazey, R.S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003).
62. Kozlowski, P.A. & Neutra, M.R. The role of mucosal immunity in prevention of HIV transmission. Curr. Mol. Med. 3, 217-228 (2003).
63. Yuki, Y., Nochi, T. & Kiyono, H. Progress towards an AIDS mucosal vaccine: An overview. Tuberculosis (Edinb) 87 (Suppl 1), S35-S44 (2007).
64. Wilson, D.P., Coplan, P.M., Wainberg, M.A. & Blower, S.M. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc. Natl Acad. Sci. USA 105, 9835-9840 (2008).
65. Bomsel, M., Fleury, S. & Zubrigen, R. Virosomes like vesicules comprising GP41 derivate antigen. In PCT/IB 2006.000466 INSERM/Mymetics/ Pevion IB 2007/000466 (2006).
66. Musey, L., Hu, Y., Eckert, L., Christensen, M., Karchmer, T. & McElrath, M.J. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J. Exp. Med. 185, 293-303 (1997).
67. Barbas, C.F. III., Kang, A.S., Lerner, R.A. & Benkovic, S.J. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc. Natl Acad. Sci. USA 88, 7978-7982 (1991).
68. de Bruin, R., Spelt, K., Mol, J., Koes, R. & Quattrocchio, F. Selection of high-affinity phage antibodies from phage display libraries. Nat. Biotechnol. 17, 397-399 (1999).
69. Fiedler, M. & Skerra, A. Use of thiophilic adsorption chromatography for the one-step purification of a bacterially produced antibody F(ab) fragment without the need for an affinity tag. Protein Expr. Purif. 17, 421-427 (1999).
70. Holl, V. AQ26 et al. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J. Immunol. 173, 6274-6283 (2004).
71. Mascola, J.R. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20, 1922-1925 (2002).
72. Bomsel, M. et al. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS 21, 13-22 (2007).
73. Bomsel, M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3 42-47 (1997).
74. Bouschbacher, M. et al. Early events in HIV transmission through a human vaginal mucosa. AIDS 22, 1257-1266 (2008).
75. Lefranc, M.P. IMGT, the international ImMunoGeneTics information system. Novartis Found Symp. 254, 126-136 (2003); discussion 136-142, 216-122, 250-122, available at http://imgt.cines.fr.